[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100588496":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":37,"locations":43,"responsibleParty":60,"collaborators":41,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":64,"sex":70,"minAge":71,"maxAge":41,"enrollmentInfo":72,"targetDuration":41,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":83,"whyStopped":41,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Chong Kun Dang Pharmaceutical","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Certirobell Tablet","EXPERIMENTAL","Everolimus",[13],"Drug: Everolimus",{"label":15,"type":16,"description":17,"interventionNames":18},"Myrept Tablet\u002FCapsule","ACTIVE_COMPARATOR","Mycophenolate mofetil",[19],"Drug: Mycophenolate mofetil Tablet\u002FCapsule",[21,26],{"type":22,"name":11,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Up to 1.5g BID(total 3g daily), PO - Check the blood concentration of Everolimus at each visit",[9],[9],{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"Mycophenolate mofetil Tablet\u002FCapsule","Up to 1.5g BID(total 3g daily), PO",[15],[31],"Myrept® Cap.\u002FTab.",[33],{"name":34,"affiliation":35,"role":36},"Jin-O Choi, MD, PhD","Samsung Medical Center","STUDY_CHAIR",[38],{"name":34,"role":39,"phone":40,"phoneExt":41,"email":42},"CONTACT","02-3410-3419",null,"choijean5@gmail.com",[44],{"facility":35,"status":41,"city":45,"state":45,"zip":46,"country":47,"countryCode":41,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Seoul","06351","South Korea",{"type":49,"coordinates":50},"Point",[51,52],126.9784,37.566,{"lat":52,"lon":51},[55,56],{"name":34,"role":39,"phone":41,"phoneExt":41,"email":42},{"name":57,"role":39,"phone":58,"phoneExt":41,"email":59},"Seyoung Jung","82-2-6373-0791","seyoung.jung@ckdpharm.com",{"type":61,"investigatorFullName":41,"investigatorTitle":41,"investigatorAffiliation":41,"oldNameTitle":41,"oldOrganization":41},"SPONSOR","100588496","phase-4-optimize-immunosuppressive-therapy-using-everolimus-and-low-dose-calcineurin-inhibitors-in-heart-transplant-patients-in-korea-100588496",false,"NCT06942156","Optimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea","A Prospective, Multicenter, Open-Label, Randomized, Comparative, Phase 4 Trial to Optimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea","OPTIMIZE-HTx","Inclusion Criteria:\n\n1. Over 19 years old\n2. Patients with stable heart transplant graft function at least 28\\~100 days post transplant.\n3. Patients who are appropriate for combination therapy with Everolimus and Calcineurin inhibitor (CNI) at the investigator's discretion\n\nExclusion Criteria:\n\n1. Recipients who have had a prior organ transplant, or who underwent a heart transplant with the simultaneous transplantation of another organ.\n2. Recipients of heart from ABO-incompatible donor\n3. Recipients of heart from the donor aged 70 or older","ALL","19 Years",{"count":73,"type":74},140,"ESTIMATED","INTERVENTIONAL",[77],"PHASE4","The purpose of this study is to evaluate the efficacy and safety of lower dose calcineurin inhibitors (CNI) in combination with Everolimus in Korean heart transplant recipients.",[80],"Heart Transplant",[82,11],"Heart transplant","NOT_YET_RECRUITING","2025-04-21",{"date":86,"type":87},"2025-04-24","ACTUAL",{"date":89,"type":74},"2025-08-14",{"date":91,"type":74},"2030-12",{"name":5,"class":6},1]